FDA Rejects Merck & Co.’s Glaucoma Treatment

The FDA rejected Merck & Co.’s glaucoma medicine tafluprost, which is also known by its brand name Saflutan and is already available in some overseas markets, according to a Reuter‘s report.

Advertisement

Merck did not issue a release or note the FDA’s reasoning behind the rejection, but included a brief mention in the company’s regulatory filing with the Securities and Exchange Commission, the report said,

Related Articles on Ophthalmology:
Study: Patients With Glaucoma Vision Loss Have Higher Fall Risk
Ophthalmologist on the Move: Dr. Rodney P. Coe Joins the Retina Group of New York
10 Points on Ophthalmology in Surgery Centers

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.